<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01425853</url>
  </required_header>
  <id_info>
    <org_study_id>DRO/IV-ART-01</org_study_id>
    <secondary_id>2010-024010-61</secondary_id>
    <nct_id>NCT01425853</nct_id>
  </id_info>
  <brief_title>Study on Efficacy and Safety of Chondroitin Sulfate + Glucosamine Hydrochloride Versus Celecoxib in Knee Osteoarthritis</brief_title>
  <acronym>MOVES</acronym>
  <official_title>Non-Inferiority Clinical Trial On The Efficacy And Safety Of Chondroitin Sulfate And Glucosamine Hydrochloride In Combination Versus Celecoxib In Patients With Knee Osteoarthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bioiberica</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bioiberica</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether the combination of Chondroitin sulfate (CS)
      and Glucosamine Hydrochloride (GH) has similar efficacy to Celecoxib (CE) in the treatment of
      patients with moderate to severe knee osteoarthritis (OA).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this study is to show that the combination treatment CS/GH has
      comparable efficacy to CE in pain reduction from baseline to 6 months of treatment measured
      with the Western Ontario and McMaster Universities Arthritis Index (WOMAC) pain subscale in
      knee OA patients with moderate to severe pain.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>WOMAC Pain Subscale</measure>
    <time_frame>6 months</time_frame>
    <description>Western Ontario &amp; McMaster Universities Osteoarthritis Index (WOMAC) Pain subscale Score Range: 0 (no pain) - 500 (maximum pain) The study was designed such that the outcome of primary interest is knee pain related to OA. The measure selected to best evaluate this is an improvement in the WOMAC pain subscales. This subscale consists of 5 items which assesses the pain during walking, using stairs, in bed, sitting or lying, and standing.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>WOMAC Stiffness Subscale</measure>
    <time_frame>6 months</time_frame>
    <description>Western Ontario &amp; McMaster Universities Osteoarthritis Index, from 0 No Stiffness to 200 Maximum Stiffness WOMAC stiffness subscale was used to measure the stiffness of the knee with pain. Two items are used to assess stiffness grade: after first waking and later in the day.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>WOMAC Function Subscale</measure>
    <time_frame>6 months</time_frame>
    <description>Western Ontario &amp; McMaster Universities Osteoarthritis Index, from 0 No Function to 1700 Maximum Function WOMAC functional limitation subscale was used to measure the functionality of the knee with pain. Seventeen items are used to assess functionality of the knee: tair use, rising from sitting, standing, bending, walking, getting in / out of a car, shopping, putting on / taking off socks, rising from bed, lying in bed, getting in / out of bath, sitting, getting on / off toilet, heavy household duties, light household duties.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Huskisson's VAS</measure>
    <time_frame>6 months</time_frame>
    <description>Visual Analogue Scale: 0 No Pain 100 Maximum Pain Huskisson's VAS measures global pain intensity. Patients were asked to quantify their disease status on a 100 mm VAS as follows: &quot;Please indicate the severity of knee pain experienced during the last 48 hours by marking a (I) through the line&quot;. Left hand marker represents &quot;No pain&quot; and right hand marker represents &quot;The worst pain imaginable&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Response as Defined by Outcome Variables for Osteoarthritis Clinical Trials - Osteoarthritis Research Society International (OMERACT-OARSI)</measure>
    <time_frame>6 months</time_frame>
    <description>The OARSI Standing Committee for Clinical Trials Response Criteria Initiative and the OMERACT committee, in concert with the international rheumatology community, has led to the development of a uniform core set of outcome measures for OA. One of the objectives was to propose a set of criteria for measurement based on multiple domains to present the results of changes after treatment in symptomatic parameters as a single variable for clinical trials.
To be considered as responder patients should met one the following criteria:
High improvement in pain or in function ≥ 50% and absolute change ≥ 20 or
Improvement in at least 2 of the 3 following:
Pain ≥ 20% and absolute change ≥ 10
Function ≥ 20% and absolute change ≥ 10
Patient's global assessment ≥ 20% and absolute change ≥ 10</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Presence of Joint Swelling</measure>
    <time_frame>6 months</time_frame>
    <description>Study knees were evaluated at each visit for the presence or absence of swelling and/or effusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Presence of Joint Effusion</measure>
    <time_frame>6 months</time_frame>
    <description>Study knees were evaluated at each visit for the presence or absence of swelling and/or effusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Consumption of Rescue Medication</measure>
    <time_frame>6 months</time_frame>
    <description>Use of rescue medication as number of paracetamol tablets 500 mg since the last visit. The tablet count was reconciled with the patient diary.
Total Number of pills per month</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's Global Assessment (PGA) and Investigator's Global Assessment (IGA) of Disease Activity</measure>
    <time_frame>6 months</time_frame>
    <description>Patients were asked to quantify their disease status on a VAS scale with range 0 mm (best) and 100 mm (worst) as follows: &quot;Considering all the ways your arthritis of the knee affects you, mark (I) on the scale how well you are doing.&quot; Left hand marker &quot;Very Well&quot;, Right hand marked &quot;Very Poor&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's and Investigator's Global Assessment of Response to Therapy</measure>
    <time_frame>6 months</time_frame>
    <description>The investigator were asked to evaluated the patient's response to therapy of the index knee by marking a (I) a VAS scale with range 0 mm (best) and 100 mm (worst) as follows: Left hand marker &quot;Excellent-Best possible anticipated response, considering the severity and stage of the disease&quot;, right hand marker &quot;None-no response, absence of drug effect&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Status According to EuroQoL</measure>
    <time_frame>6 months</time_frame>
    <description>EuroQoL-5D was a standardized instrument for use as a measure of health outcome that provides a simple descriptive profile and a single index value for health status. It was assessed at all of the study visits.
The EQ-5D-3L essentially consists of 2 pages - the EQ-5D descriptive system (page 2) and the EQ visual analogue scale (EQ VAS) (page 3). The EQ-5D-3L descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: no problems, some problems, extreme problems. Total scale range for each dimension reported is 1 to 3.
The EQ VAS records the respondent's self-rated health on a vertical, visual analogue scale where the endpoints are labelled 'Best imaginable health state' and 'Worst imaginable health state'. This information can be used as a quantitative measure of health outcome as judged by the individual respondents.
Total scale range for VAS dimension reported is 0 to 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With at Least One Adverse Events</measure>
    <time_frame>6 months</time_frame>
    <description>The safety evaluation was done in the set of randomized patients who took at least one dose of the medication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Adverse Events Defined by Relationship With Treatment</measure>
    <time_frame>6 months</time_frame>
    <description>The safety evaluation was done in the set of randomized patients who took at least one dose of the medication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarker Analysis</measure>
    <time_frame>6 months</time_frame>
    <description>The following biomarkers will be evaluated: COMP, Coll2-1, Coll2-1 NO2 and Fib3-2</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">606</enrollment>
  <condition>Knee Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Chondroitin/Glucosamine (Droglican)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Active ingredients: Chondroitin sulfate, 200 mg and Glucosamine hydrochloride 250 mg.
Pharmacotherapeutic group: Other specific antirheumatic agents. Anatomical Therapeutic Chemical Classification System (ATC) code: M01CX.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Celecoxib</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Active ingredient: Celecoxib, 200 mg. Pharmacotherapeutic group: Coxibs. ATC code: M01AH.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chondroitin/Glucosamine (Droglican)</intervention_name>
    <description>Experimental</description>
    <arm_group_label>Chondroitin/Glucosamine (Droglican)</arm_group_label>
    <other_name>Chondroitin sulfate/ Glucosamine hydrochloride</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Celecoxib</intervention_name>
    <description>Active comparator</description>
    <arm_group_label>Celecoxib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  At least 40 years of age

          -  Primary OA of the knee according to the American College of Rheumatology (ACR)
             criteria

          -  OA of radiological stages II or III according to Kellgren and Lawrence

          -  Patients with moderate-severe knee pain

        Exclusion Criteria:

          -  Subjects with active malignancy of any type or history of a malignancy within the last
             five years

          -  Concurrent arthritic disease (antecedents and/or current signs) that could confound or
             interfere with the evaluation of pain efficacy such as chondrocalcinosis, Paget's
             disease of the ipsilateral limb to the target knee, rheumatoid arthritis, aseptic
             osteonecrosis, gout, septic arthritis, ochronosis, acromegaly, haemochromatosis,
             Wilson's disease, osteochondromatosis seronegative spondylo-arthropathy, mixed
             connective tissue disease, collagen vascular disease, psoriasis, inflammatory bowel
             disease

          -  Pain in other parts of the body greater than the knee pain that could interfere with
             the evaluation of the index joint

          -  Patients with fibromyalgia

          -  Subjects with a history of heart attack or stroke, or who have experienced chest pain
             related to heart disease, or who have had serious diseases of the heart

          -  Subjects with high risk of cardiovascular (CV) events

          -  Subjects with any active acute or chronic infections requiring antimicrobial therapy,
             or serious viral (e.g., hepatitis, herpes zoster, HIV positivity) or fungal infections

          -  Subjects with a history of recurrent Upper Gastrointestinal (UGI) ulceration or active
             inflammatory bowel disease (e.g., Crohn's disease or ulcerative colitis), a
             significant coagulation defect

          -  Subjects who have been diagnosed as having or have been treated for oesophageal,
             gastric, pyloric channel, or duodenal ulceration within 30 days prior to receiving the
             first dose of study medication

          -  Washout period for OA treatments before beginning the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jordi Monfort, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Principal Investigator</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 25, 2011</study_first_submitted>
  <study_first_submitted_qc>August 29, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 30, 2011</study_first_posted>
  <results_first_submitted>July 20, 2015</results_first_submitted>
  <results_first_submitted_qc>January 29, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 26, 2016</results_first_posted>
  <last_update_submitted>January 29, 2016</last_update_submitted>
  <last_update_submitted_qc>January 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Celecoxib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Chondroitin Sulfate/ Glucosamine Hydrochloride (Droglican)</title>
          <description>Active ingredients: Chondroitin sulfate, 200 mg and Glucosamine hydrochloride 250 mg.
Pharmacotherapeutic group: Other specific antirheumatic agents. ATC code: M01CX.
Chondroitin sulfate/ Glucosamine hydrochloride</description>
        </group>
        <group group_id="P2">
          <title>Celecoxib</title>
          <description>Active ingredient: Celecoxib, 200 mg. Pharmacotherapeutic group: Coxibs. ATC code: M01AH.
Celecoxib</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="304"/>
                <participants group_id="P2" count="302"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Population</title>
              <participants_list>
                <participants group_id="P1" count="304"/>
                <participants group_id="P2" count="299"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Per Protocol (PP)</title>
              <participants_list>
                <participants group_id="P1" count="264"/>
                <participants group_id="P2" count="258"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="240"/>
                <participants group_id="P2" count="225"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="64"/>
                <participants group_id="P2" count="77"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>PP population was defined as all randomized patients who met the inclusion criteria, received study medication, had a baseline efficacy measurement and at least one corresponding post-baseline efficacy measurement (for the main efficacy variable) and did not present major violations of the protocol (n=522).</population>
      <group_list>
        <group group_id="B1">
          <title>Chondroitin Sulfate/ Glucosamine Hydrochloride (Droglican)</title>
          <description>Active ingredients: Chondroitin sulfate, 200 mg and Glucosamine hydrochloride 250 mg.
Pharmacotherapeutic group: Other specific antirheumatic agents. Anatomical Therapeutic Chemical Classification System (ATC) code: M01CX.
Chondroitin sulfate/ Glucosamine hydrochloride</description>
        </group>
        <group group_id="B2">
          <title>Celecoxib</title>
          <description>Active ingredient: Celecoxib, 200 mg. Pharmacotherapeutic group: Coxibs. ATC code: M01AH.
Celecoxib</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="264"/>
            <count group_id="B2" value="258"/>
            <count group_id="B3" value="522"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.22" spread="8.81"/>
                    <measurement group_id="B2" value="63.16" spread="9.02"/>
                    <measurement group_id="B3" value="62.68" spread="8.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="229"/>
                    <measurement group_id="B2" value="209"/>
                    <measurement group_id="B3" value="438"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>WOMAC Pain Subscale</title>
          <description>Western Ontario &amp; McMaster Universities Osteoarthritis Index, from 0 No Pain to 500 Maximum Pain</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="371.97" spread="41.76"/>
                    <measurement group_id="B2" value="370.60" spread="41.15"/>
                    <measurement group_id="B3" value="371.29" spread="41.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>WOMAC Pain Subscale</title>
        <description>Western Ontario &amp; McMaster Universities Osteoarthritis Index (WOMAC) Pain subscale Score Range: 0 (no pain) - 500 (maximum pain) The study was designed such that the outcome of primary interest is knee pain related to OA. The measure selected to best evaluate this is an improvement in the WOMAC pain subscales. This subscale consists of 5 items which assesses the pain during walking, using stairs, in bed, sitting or lying, and standing.</description>
        <time_frame>6 months</time_frame>
        <population>Imputed data on PP population</population>
        <group_list>
          <group group_id="O1">
            <title>Chondroitin Sulfate/ Glucosamine Hydrochloride (Droglican)</title>
            <description>Active ingredients: Chondroitin sulfate, 200 mg and Glucosamine hydrochloride 250 mg.
Pharmacotherapeutic group: Other specific antirheumatic agents. ATC code: M01CX.
Chondroitin sulfate/ Glucosamine hydrochloride</description>
          </group>
          <group group_id="O2">
            <title>Celecoxib</title>
            <description>Active ingredient: Celecoxib, 200 mg. Pharmacotherapeutic group: Coxibs. ATC code: M01AH.
Celecoxib</description>
          </group>
        </group_list>
        <measure>
          <title>WOMAC Pain Subscale</title>
          <description>Western Ontario &amp; McMaster Universities Osteoarthritis Index (WOMAC) Pain subscale Score Range: 0 (no pain) - 500 (maximum pain) The study was designed such that the outcome of primary interest is knee pain related to OA. The measure selected to best evaluate this is an improvement in the WOMAC pain subscales. This subscale consists of 5 items which assesses the pain during walking, using stairs, in bed, sitting or lying, and standing.</description>
          <population>Imputed data on PP population</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="264"/>
                <count group_id="O2" value="258"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="185.79" spread="7.43"/>
                    <measurement group_id="O2" value="184.67" spread="7.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>WOMAC Stiffness Subscale</title>
        <description>Western Ontario &amp; McMaster Universities Osteoarthritis Index, from 0 No Stiffness to 200 Maximum Stiffness WOMAC stiffness subscale was used to measure the stiffness of the knee with pain. Two items are used to assess stiffness grade: after first waking and later in the day.</description>
        <time_frame>6 months</time_frame>
        <population>ADO on PP population</population>
        <group_list>
          <group group_id="O1">
            <title>Chondroitin Sulfate/ Glucosamine Hydrochloride (Droglican)</title>
            <description>Active ingredients: Chondroitin sulfate, 200 mg and Glucosamine hydrochloride 250 mg.
Pharmacotherapeutic group: Other specific antirheumatic agents. ATC code: M01CX.
Chondroitin sulfate/ Glucosamine hydrochloride</description>
          </group>
          <group group_id="O2">
            <title>Celecoxib</title>
            <description>Active ingredient: Celecoxib, 200 mg. Pharmacotherapeutic group: Coxibs. ATC code: M01AH.
Celecoxib</description>
          </group>
        </group_list>
        <measure>
          <title>WOMAC Stiffness Subscale</title>
          <description>Western Ontario &amp; McMaster Universities Osteoarthritis Index, from 0 No Stiffness to 200 Maximum Stiffness WOMAC stiffness subscale was used to measure the stiffness of the knee with pain. Two items are used to assess stiffness grade: after first waking and later in the day.</description>
          <population>ADO on PP population</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="264"/>
                <count group_id="O2" value="258"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="130.15" spread="34.97"/>
                    <measurement group_id="O2" value="129.48" spread="37.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>180 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.06" spread="2.92"/>
                    <measurement group_id="O2" value="65.78" spread="2.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>WOMAC Function Subscale</title>
        <description>Western Ontario &amp; McMaster Universities Osteoarthritis Index, from 0 No Function to 1700 Maximum Function WOMAC functional limitation subscale was used to measure the functionality of the knee with pain. Seventeen items are used to assess functionality of the knee: tair use, rising from sitting, standing, bending, walking, getting in / out of a car, shopping, putting on / taking off socks, rising from bed, lying in bed, getting in / out of bath, sitting, getting on / off toilet, heavy household duties, light household duties.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Chondroitin Sulfate/ Glucosamine Hydrochloride (Droglican)</title>
            <description>Active ingredients: Chondroitin sulfate, 200 mg and Glucosamine hydrochloride 250 mg.
Pharmacotherapeutic group: Other specific antirheumatic agents. ATC code: M01CX.
Chondroitin sulfate/ Glucosamine hydrochloride</description>
          </group>
          <group group_id="O2">
            <title>Celecoxib</title>
            <description>Active ingredient: Celecoxib, 200 mg. Pharmacotherapeutic group: Coxibs. ATC code: M01AH.
Celecoxib</description>
          </group>
        </group_list>
        <measure>
          <title>WOMAC Function Subscale</title>
          <description>Western Ontario &amp; McMaster Universities Osteoarthritis Index, from 0 No Function to 1700 Maximum Function WOMAC functional limitation subscale was used to measure the functionality of the knee with pain. Seventeen items are used to assess functionality of the knee: tair use, rising from sitting, standing, bending, walking, getting in / out of a car, shopping, putting on / taking off socks, rising from bed, lying in bed, getting in / out of bath, sitting, getting on / off toilet, heavy household duties, light household duties.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="264"/>
                <count group_id="O2" value="258"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1131.40" spread="242.68"/>
                    <measurement group_id="O2" value="1111.60" spread="267.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>180 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="616.96" spread="23.51"/>
                    <measurement group_id="O2" value="595.78" spread="24.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Huskisson’s VAS</title>
        <description>Visual Analogue Scale: 0 No Pain 100 Maximum Pain Huskisson’s VAS measures global pain intensity. Patients were asked to quantify their disease status on a 100 mm VAS as follows: “Please indicate the severity of knee pain experienced during the last 48 hours by marking a (I) through the line”. Left hand marker represents “No pain” and right hand marker represents “The worst pain imaginable”.</description>
        <time_frame>6 months</time_frame>
        <population>ADO on PP population</population>
        <group_list>
          <group group_id="O1">
            <title>Chondroitin Sulfate/ Glucosamine Hydrochloride (Droglican)</title>
            <description>Active ingredients: Chondroitin sulfate, 200 mg and Glucosamine hydrochloride 250 mg.
Pharmacotherapeutic group: Other specific antirheumatic agents. ATC code: M01CX.
Chondroitin sulfate/ Glucosamine hydrochloride</description>
          </group>
          <group group_id="O2">
            <title>Celecoxib</title>
            <description>Active ingredient: Celecoxib, 200 mg. Pharmacotherapeutic group: Coxibs. ATC code: M01AH.
Celecoxib</description>
          </group>
        </group_list>
        <measure>
          <title>Huskisson’s VAS</title>
          <description>Visual Analogue Scale: 0 No Pain 100 Maximum Pain Huskisson’s VAS measures global pain intensity. Patients were asked to quantify their disease status on a 100 mm VAS as follows: “Please indicate the severity of knee pain experienced during the last 48 hours by marking a (I) through the line”. Left hand marker represents “No pain” and right hand marker represents “The worst pain imaginable”.</description>
          <population>ADO on PP population</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="264"/>
                <count group_id="O2" value="258"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.79" spread="15.12"/>
                    <measurement group_id="O2" value="73.47" spread="15.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>180 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.86" spread="1.61"/>
                    <measurement group_id="O2" value="37.64" spread="1.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Response as Defined by Outcome Variables for Osteoarthritis Clinical Trials - Osteoarthritis Research Society International (OMERACT-OARSI)</title>
        <description>The OARSI Standing Committee for Clinical Trials Response Criteria Initiative and the OMERACT committee, in concert with the international rheumatology community, has led to the development of a uniform core set of outcome measures for OA. One of the objectives was to propose a set of criteria for measurement based on multiple domains to present the results of changes after treatment in symptomatic parameters as a single variable for clinical trials.
To be considered as responder patients should met one the following criteria:
High improvement in pain or in function ≥ 50% and absolute change ≥ 20 or
Improvement in at least 2 of the 3 following:
Pain ≥ 20% and absolute change ≥ 10
Function ≥ 20% and absolute change ≥ 10
Patient’s global assessment ≥ 20% and absolute change ≥ 10</description>
        <time_frame>6 months</time_frame>
        <population>ADO on PP population</population>
        <group_list>
          <group group_id="O1">
            <title>Chondroitin Sulfate/ Glucosamine Hydrochloride (Droglican)</title>
            <description>Active ingredients: Chondroitin sulfate, 200 mg and Glucosamine hydrochloride 250 mg.
Pharmacotherapeutic group: Other specific antirheumatic agents. ATC code: M01CX.
Chondroitin sulfate/ Glucosamine hydrochloride</description>
          </group>
          <group group_id="O2">
            <title>Celecoxib</title>
            <description>Active ingredient: Celecoxib, 200 mg. Pharmacotherapeutic group: Coxibs. ATC code: M01AH.
Celecoxib</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Response as Defined by Outcome Variables for Osteoarthritis Clinical Trials - Osteoarthritis Research Society International (OMERACT-OARSI)</title>
          <description>The OARSI Standing Committee for Clinical Trials Response Criteria Initiative and the OMERACT committee, in concert with the international rheumatology community, has led to the development of a uniform core set of outcome measures for OA. One of the objectives was to propose a set of criteria for measurement based on multiple domains to present the results of changes after treatment in symptomatic parameters as a single variable for clinical trials.
To be considered as responder patients should met one the following criteria:
High improvement in pain or in function ≥ 50% and absolute change ≥ 20 or
Improvement in at least 2 of the 3 following:
Pain ≥ 20% and absolute change ≥ 10
Function ≥ 20% and absolute change ≥ 10
Patient’s global assessment ≥ 20% and absolute change ≥ 10</description>
          <population>ADO on PP population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="236"/>
                <count group_id="O2" value="221"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.7"/>
                    <measurement group_id="O2" value="79.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Presence of Joint Swelling</title>
        <description>Study knees were evaluated at each visit for the presence or absence of swelling and/or effusion.</description>
        <time_frame>6 months</time_frame>
        <population>ADO on PP population</population>
        <group_list>
          <group group_id="O1">
            <title>Chondroitin Sulfate/ Glucosamine Hydrochloride (Droglican)</title>
            <description>Active ingredients: Chondroitin sulfate, 200 mg and Glucosamine hydrochloride 250 mg.
Pharmacotherapeutic group: Other specific antirheumatic agents. ATC code: M01CX.
Chondroitin sulfate/ Glucosamine hydrochloride</description>
          </group>
          <group group_id="O2">
            <title>Celecoxib</title>
            <description>Active ingredient: Celecoxib, 200 mg. Pharmacotherapeutic group: Coxibs. ATC code: M01AH.
Celecoxib</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Presence of Joint Swelling</title>
          <description>Study knees were evaluated at each visit for the presence or absence of swelling and/or effusion.</description>
          <population>ADO on PP population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="236"/>
                <count group_id="O2" value="221"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.9"/>
                    <measurement group_id="O2" value="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Presence of Joint Effusion</title>
        <description>Study knees were evaluated at each visit for the presence or absence of swelling and/or effusion.</description>
        <time_frame>6 months</time_frame>
        <population>ADO on PP population</population>
        <group_list>
          <group group_id="O1">
            <title>Chondroitin Sulfate/ Glucosamine Hydrochloride (Droglican)</title>
            <description>Active ingredients: Chondroitin sulfate, 200 mg and Glucosamine hydrochloride 250 mg.
Pharmacotherapeutic group: Other specific antirheumatic agents. ATC code: M01CX.
Chondroitin sulfate/ Glucosamine hydrochloride</description>
          </group>
          <group group_id="O2">
            <title>Celecoxib</title>
            <description>Active ingredient: Celecoxib, 200 mg. Pharmacotherapeutic group: Coxibs. ATC code: M01AH.
Celecoxib</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Presence of Joint Effusion</title>
          <description>Study knees were evaluated at each visit for the presence or absence of swelling and/or effusion.</description>
          <population>ADO on PP population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="236"/>
                <count group_id="O2" value="221"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1"/>
                    <measurement group_id="O2" value="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Consumption of Rescue Medication</title>
        <description>Use of rescue medication as number of paracetamol tablets 500 mg since the last visit. The tablet count was reconciled with the patient diary.
Total Number of pills per month</description>
        <time_frame>6 months</time_frame>
        <population>Consumption of rescue medication (number of daily tablets consumed). ADO on PP population. daily tablets consumed/month</population>
        <group_list>
          <group group_id="O1">
            <title>Chondroitin Sulfate/ Glucosamine Hydrochloride (Droglican)</title>
            <description>Active ingredients: Chondroitin sulfate, 200 mg and Glucosamine hydrochloride 250 mg.
Pharmacotherapeutic group: Other specific antirheumatic agents. ATC code: M01CX.
Chondroitin sulfate/ Glucosamine hydrochloride</description>
          </group>
          <group group_id="O2">
            <title>Celecoxib</title>
            <description>Active ingredient: Celecoxib, 200 mg. Pharmacotherapeutic group: Coxibs. ATC code: M01AH.
Celecoxib</description>
          </group>
        </group_list>
        <measure>
          <title>Consumption of Rescue Medication</title>
          <description>Use of rescue medication as number of paracetamol tablets 500 mg since the last visit. The tablet count was reconciled with the patient diary.
Total Number of pills per month</description>
          <population>Consumption of rescue medication (number of daily tablets consumed). ADO on PP population. daily tablets consumed/month</population>
          <units>daily tablets consumed/month</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="264"/>
                <count group_id="O2" value="258"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.0" spread="2.6"/>
                    <measurement group_id="O2" value="29.0" spread="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient’s Global Assessment (PGA) and Investigator's Global Assessment (IGA) of Disease Activity</title>
        <description>Patients were asked to quantify their disease status on a VAS scale with range 0 mm (best) and 100 mm (worst) as follows: “Considering all the ways your arthritis of the knee affects you, mark (I) on the scale how well you are doing.” Left hand marker “Very Well”, Right hand marked “Very Poor”.</description>
        <time_frame>6 months</time_frame>
        <population>Patient and Investigator's global assessment of disease activity. ADO on PP population</population>
        <group_list>
          <group group_id="O1">
            <title>Chondroitin Sulfate/ Glucosamine Hydrochloride (Droglican)</title>
            <description>Active ingredients: Chondroitin sulfate, 200 mg and Glucosamine hydrochloride 250 mg.
Pharmacotherapeutic group: Other specific antirheumatic agents. ATC code: M01CX.
Chondroitin sulfate/ Glucosamine hydrochloride</description>
          </group>
          <group group_id="O2">
            <title>Celecoxib</title>
            <description>Active ingredient: Celecoxib, 200 mg. Pharmacotherapeutic group: Coxibs. ATC code: M01AH.
Celecoxib</description>
          </group>
        </group_list>
        <measure>
          <title>Patient’s Global Assessment (PGA) and Investigator's Global Assessment (IGA) of Disease Activity</title>
          <description>Patients were asked to quantify their disease status on a VAS scale with range 0 mm (best) and 100 mm (worst) as follows: “Considering all the ways your arthritis of the knee affects you, mark (I) on the scale how well you are doing.” Left hand marker “Very Well”, Right hand marked “Very Poor”.</description>
          <population>Patient and Investigator's global assessment of disease activity. ADO on PP population</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="264"/>
                <count group_id="O2" value="258"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PGA Activity Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.11" spread="17.34"/>
                    <measurement group_id="O2" value="69.41" spread="16.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PGA Activity 180 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.35" spread="1.54"/>
                    <measurement group_id="O2" value="36.88" spread="1.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IGA Activity Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.2" spread="15.54"/>
                    <measurement group_id="O2" value="63.28" spread="14.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IGA Activity 180 daus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.33" spread="1.39"/>
                    <measurement group_id="O2" value="33.40" spread="1.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient’s and Investigator's Global Assessment of Response to Therapy</title>
        <description>The investigator were asked to evaluated the patient’s response to therapy of the index knee by marking a (I) a VAS scale with range 0 mm (best) and 100 mm (worst) as follows: Left hand marker “Excellent-Best possible anticipated response, considering the severity and stage of the disease”, right hand marker “None-no response, absence of drug effect”.</description>
        <time_frame>6 months</time_frame>
        <population>Investigator and Patient's global assessment assessment of response to therapy. ADO on PP population.</population>
        <group_list>
          <group group_id="O1">
            <title>Chondroitin Sulfate/ Glucosamine Hydrochloride (Droglican)</title>
            <description>Active ingredients: Chondroitin sulfate, 200 mg and Glucosamine hydrochloride 250 mg.
Pharmacotherapeutic group: Other specific antirheumatic agents. ATC code: M01CX.
Chondroitin sulfate/ Glucosamine hydrochloride</description>
          </group>
          <group group_id="O2">
            <title>Celecoxib</title>
            <description>Active ingredient: Celecoxib, 200 mg. Pharmacotherapeutic group: Coxibs. ATC code: M01AH.
Celecoxib</description>
          </group>
        </group_list>
        <measure>
          <title>Patient’s and Investigator's Global Assessment of Response to Therapy</title>
          <description>The investigator were asked to evaluated the patient’s response to therapy of the index knee by marking a (I) a VAS scale with range 0 mm (best) and 100 mm (worst) as follows: Left hand marker “Excellent-Best possible anticipated response, considering the severity and stage of the disease”, right hand marker “None-no response, absence of drug effect”.</description>
          <population>Investigator and Patient's global assessment assessment of response to therapy. ADO on PP population.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="264"/>
                <count group_id="O2" value="258"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PGA Therapy Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.59" spread="1.55"/>
                    <measurement group_id="O2" value="45.9" spread="1.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PGA Therapy 180 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.85" spread="1.70"/>
                    <measurement group_id="O2" value="36.04" spread="1.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IGA Therapy Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.4" spread="1.43"/>
                    <measurement group_id="O2" value="42.25" spread="1.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IGA Therapy 180 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.72" spread="1.6"/>
                    <measurement group_id="O2" value="33.83" spread="1.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Health Status According to EuroQoL</title>
        <description>EuroQoL-5D was a standardized instrument for use as a measure of health outcome that provides a simple descriptive profile and a single index value for health status. It was assessed at all of the study visits.
The EQ-5D-3L essentially consists of 2 pages - the EQ-5D descriptive system (page 2) and the EQ visual analogue scale (EQ VAS) (page 3). The EQ-5D-3L descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: no problems, some problems, extreme problems. Total scale range for each dimension reported is 1 to 3.
The EQ VAS records the respondent’s self-rated health on a vertical, visual analogue scale where the endpoints are labelled ‘Best imaginable health state’ and ‘Worst imaginable health state’. This information can be used as a quantitative measure of health outcome as judged by the individual respondents.
Total scale range for VAS dimension reported is 0 to 100.</description>
        <time_frame>6 months</time_frame>
        <population>ADO on PP population</population>
        <group_list>
          <group group_id="O1">
            <title>Chondroitin Sulfate/ Glucosamine Hydrochloride (Droglican)</title>
            <description>Active ingredients: Chondroitin sulfate, 200 mg and Glucosamine hydrochloride 250 mg.
Pharmacotherapeutic group: Other specific antirheumatic agents. Anatomical Therapeutic Chemical Classification System (ATC) code: M01CX.
Chondroitin sulfate/ Glucosamine hydrochloride</description>
          </group>
          <group group_id="O2">
            <title>Celecoxib</title>
            <description>Active ingredient: Celecoxib, 200 mg. Pharmacotherapeutic group: Coxibs. ATC code: M01AH.
Celecoxib</description>
          </group>
        </group_list>
        <measure>
          <title>Health Status According to EuroQoL</title>
          <description>EuroQoL-5D was a standardized instrument for use as a measure of health outcome that provides a simple descriptive profile and a single index value for health status. It was assessed at all of the study visits.
The EQ-5D-3L essentially consists of 2 pages - the EQ-5D descriptive system (page 2) and the EQ visual analogue scale (EQ VAS) (page 3). The EQ-5D-3L descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: no problems, some problems, extreme problems. Total scale range for each dimension reported is 1 to 3.
The EQ VAS records the respondent’s self-rated health on a vertical, visual analogue scale where the endpoints are labelled ‘Best imaginable health state’ and ‘Worst imaginable health state’. This information can be used as a quantitative measure of health outcome as judged by the individual respondents.
Total scale range for VAS dimension reported is 0 to 100.</description>
          <population>ADO on PP population</population>
          <units>points</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="264"/>
                <count group_id="O2" value="258"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mobility Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.84" spread="0.37"/>
                    <measurement group_id="O2" value="1.84" spread="0.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mobility 180 Days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.52" spread="0.033"/>
                    <measurement group_id="O2" value="1.46" spread="0.034"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Self-care Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.39" spread="0.49"/>
                    <measurement group_id="O2" value="1.44" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Self-care 180 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.19" spread="0.026"/>
                    <measurement group_id="O2" value="1.21" spread="0.027"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Usual activities Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.78" spread="0.44"/>
                    <measurement group_id="O2" value="1.79" spread="0.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Usual activities 180 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.42" spread="0.033"/>
                    <measurement group_id="O2" value="1.42" spread="0.034"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain Discomfort Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.25" spread="0.43"/>
                    <measurement group_id="O2" value="2.27" spread="0.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain Discomfort 180 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.84" spread="0.032"/>
                    <measurement group_id="O2" value="1.86" spread="0.033"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anxiety depression baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.70" spread="0.58"/>
                    <measurement group_id="O2" value="1.60" spread="0.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anxiety depression 180 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.43" spread="0.038"/>
                    <measurement group_id="O2" value="1.34" spread="0.035"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VAS Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.545" spread="20.33"/>
                    <measurement group_id="O2" value="52.488" spread="20.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VAS 180 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.080" spread="1.28"/>
                    <measurement group_id="O2" value="70.219" spread="1.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With at Least One Adverse Events</title>
        <description>The safety evaluation was done in the set of randomized patients who took at least one dose of the medication</description>
        <time_frame>6 months</time_frame>
        <population>Safety population</population>
        <group_list>
          <group group_id="O1">
            <title>Chondroitin Sulfate/ Glucosamine Hydrochloride (Droglican)</title>
            <description>Active ingredients: Chondroitin sulfate, 200 mg and Glucosamine hydrochloride 250 mg.
Pharmacotherapeutic group: Other specific antirheumatic agents. Anatomical Therapeutic Chemical Classification System (ATC) code: M01CX.
Chondroitin sulfate/ Glucosamine hydrochloride</description>
          </group>
          <group group_id="O2">
            <title>Celecoxib</title>
            <description>Active ingredient: Celecoxib, 200 mg. Pharmacotherapeutic group: Coxibs. ATC code: M01AH.
Celecoxib</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With at Least One Adverse Events</title>
          <description>The safety evaluation was done in the set of randomized patients who took at least one dose of the medication</description>
          <population>Safety population</population>
          <units>number of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="304"/>
                <count group_id="O2" value="299"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="155"/>
                    <measurement group_id="O2" value="151"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Adverse Events Defined by Relationship With Treatment</title>
        <description>The safety evaluation was done in the set of randomized patients who took at least one dose of the medication</description>
        <time_frame>6 months</time_frame>
        <population>Safety population</population>
        <group_list>
          <group group_id="O1">
            <title>Chondroitin Sulfate/ Glucosamine Hydrochloride (Droglican)</title>
            <description>Active ingredients: Chondroitin sulfate, 200 mg and Glucosamine hydrochloride 250 mg.
Pharmacotherapeutic group: Other specific antirheumatic agents. Anatomical Therapeutic Chemical Classification System (ATC) code: M01CX.
Chondroitin sulfate/ Glucosamine hydrochloride</description>
          </group>
          <group group_id="O2">
            <title>Celecoxib</title>
            <description>Active ingredient: Celecoxib, 200 mg. Pharmacotherapeutic group: Coxibs. ATC code: M01AH.
Celecoxib</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Adverse Events Defined by Relationship With Treatment</title>
          <description>The safety evaluation was done in the set of randomized patients who took at least one dose of the medication</description>
          <population>Safety population</population>
          <units>number of events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="304"/>
                <count group_id="O2" value="299"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Treatment-related AEs: Definitive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment-related AEs: Possibly</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment-related AEs: Probably</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment-related AEs: Non-appraisable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment-related AEs: unlikely or unrelated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84"/>
                    <measurement group_id="O2" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Biomarker Analysis</title>
        <description>The following biomarkers will be evaluated: COMP, Coll2-1, Coll2-1 NO2 and Fib3-2</description>
        <time_frame>6 months</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Chondroitin Sulfate/ Glucosamine Hydrochloride (Droglican)</title>
          <description>Active ingredients: Chondroitin sulfate, 200 mg and Glucosamine hydrochloride 250 mg.
Pharmacotherapeutic group: Other specific antirheumatic agents. ATC code: M01CX.
Chondroitin sulfate/ Glucosamine hydrochloride</description>
        </group>
        <group group_id="E2">
          <title>Celecoxib</title>
          <description>Active ingredient: Celecoxib, 200 mg. Pharmacotherapeutic group: Coxibs. ATC code: M01AH.
Celecoxib</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="299"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="299"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="299"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Helicobacter gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="299"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="299"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Grand mal convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="299"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory Distress</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="299"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Actinic keratosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Dermatitis psoriasiform</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="299"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Carpal tunnel decompression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Hysterectomy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Obesity surgery</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="299"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="299"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="119" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="112" subjects_at_risk="299"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain upper</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Tootache</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="304"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="299"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="304"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="30" subjects_affected="26" subjects_at_risk="304"/>
                <counts group_id="E2" events="26" subjects_affected="23" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="299"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="304"/>
                <counts group_id="E2" events="10" subjects_affected="6" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" events="27" subjects_affected="20" subjects_at_risk="304"/>
                <counts group_id="E2" events="11" subjects_affected="9" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E2" events="7" subjects_affected="4" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Neck Pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="304"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="304"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="299"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="56" subjects_affected="25" subjects_at_risk="304"/>
                <counts group_id="E2" events="93" subjects_affected="31" subjects_at_risk="299"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="304"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="304"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="299"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical R&amp;D Manager</name_or_title>
      <organization>Bioiberica</organization>
      <phone>+34934904908</phone>
      <email>mherrero@bioiberica.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

